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Abstract
Background: Human papillomavirus (HPV) infection is a causative factor for cervical cancer. Early detection of high
risk HPV types might help to identify women at high risk of cervical cancer. The aim of the present study was to
examine the HPV prevalence and distribution in cervical smears in a sample of Greek women attending a
gynecological outpatient clinic and to explore the determinants of the infection.
Methods: A total of 225 women were studied. All women underwent a regular gynecological control. 35 HPV
types were studied; 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71,
72, 73, 81, 82, 83, 84, 85 and 89. Also, basic demographic information, sociodemographic characteristics and sexual
behavior were recorded.
Results: HPV was detected in 22.7% of the study population. The percentage of the newly diagnosed women with
HPV infection was 17.3%. HPV-16 was the most common type detected (5.3%) followed by HPV-53 (4.9%). 66.2% of
the study participants had a Pap test during the last year without any abnormalities. HPV infection was related
positively with alcohol consumption (OR: 2.19, 95% CI: 1.04-4.63, P = 0.04) and number of sexual partners (OR: 2.16,
95% CI: 1.44-3.25, P < 0.001), and negatively with age (OR: 0.93, 95% CI: 0.87-0.99, P = 0.03), and monthly income
(OR: 0.63, 95% CI: 0.44-0.89, P = 0.01).
Conclusion: The prevalence of HPV in women attending an outpatient clinic is high. Number of sexual partners
and alcohol consumption were the most significant risk factors for HPV infection, followed by young age and
lower income.
Background
Cervical cancer is the second most common cancer in
women worldwide [1]. Several studies have strongly
implicated human papillomavirus (HPV) infection as a
causative factor in the development of cervical cancer
[2,3]. Based on their association with cervical cancer,
HPV can be grouped to high-risk (such as HPV-16, -18,
-31, and -45) and low-risk HPV types (such as 6, 11, 42,
43, and 44) [4]. High-risk HPV types are present in over
99% of cervical cancers and in the vast majority of cases
of high grade cervical intraepithelial neoplasia [5,6].
Worldwide, approximately, 70% of cervical cancers are
due to HPV types 16 and 18 [3].
Women with normal cervical cytology who are
infected with high risk HPV type have an approximately
100-fold increased risk of developing cervical cancer
compared to uninfected women [7]. Therefore, it has
been suggested that high risk HPV detection might be
used as a tool to identify women at high risk of cervical
cancer, in addition to Pap smears [7,8]. Furthermore,
the development of HPV vaccines and implementation
of vaccination programs might help to reduce the bur-
den of disease [9]. Especially, vaccination against HPV
types 16 and 18 potentially prevents more than two
thirds of cervical cancer cases worldwide. However, the
impact of an HPV vaccination in different geographical
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16 and 18 in the different populations [10].
Since, the prevalence of the high risk HPV types varies
among different populations we conducted the present
study in order to examine the HPV prevalence and dis-
tribution in cervical smears in a sample of Greek
women attending a gynecological outpatient clinic and
to explore the determinants of the infection.
Methods
Population
The study population consisted of a consecutive sample
of 225 women attending the gynecological outpatient
clinic of the Maternal and Perinatal Hospital “Elena
Venizelou” between October 2007 and May 2008, for
regular gynecological control. “Elena Venizelou” Hospi-
tal is a tertiary maternal hospital responsible for the
greater region of Athens, the capital of Greece. Pregnant
women or women with a recent delivery were not
enrolled into the study. The refusal rate was low; only 2
women denied taking part into the study.
Basic demographic information, sociodemographic
characteristics, medical history, smoking status, alcohol
consumption and sexual and reproductive behaviour
was obtained at the time of the gynecological visit by a
study nurse. Additional questions were asked on age at
first sex, number of lifetime partners, past history of
sexually transmitted infections, and use of a condom.
Participants were considered as newly diagnosed cases
for HPV infection if they had a negative history for
HPV infection according to their medical records. In
addition, newly diagnosed cases included women who
had never been screened for HPV infection. Subjects
were considered as non-smokers if they have never
smoked or if they had given up smoking for at least
three consecutive years. Heavy drinking was defined as
consuming an average of more than 1 drink per day.
Participants were stratified according to their monthly
income and education level as it is stated at Additional
file 1, Table S1. Females whose monthly incomes did
not exceed 1,000 Euros were considered as low income.
High education level was defined as attending a college
or a university.
All subjects underwent their scheduled examination,
which included the placement of a speculum in the
vagina, visualization of the cervix, and collection of cer-
vical cells using a wooden Ayre spatula and endocervical
brush. After the preparation of a standard cervical
smear, the remaining cells were placed in tubes with
0.9% saline and stored at -20°C prepared for HPV mole-
cular analysis. Pap smears were classified according to
the Bethesda system by local cytopathologists.
The Hospital’s ethical committee provided approval
for this study. All participants gave their written consent
before enrollment to the study. The study was in accor-
dance with the Helsinki declaration.
HPV DNA Detection Techniques
Nucleic acid isolation
The cervical cells removed from the swabs and centri-
fuged in order to be in a pellet form. The supernatant
discarded and the remaining cells were dissolved in 100
μl 1× Phosphate Buffer Saline (PBS). The dissolved cells
transferred to 200 μl Tissue Lysis Buffer and 20 μlP r o -
teinase K according the instruction manual of CLINI-
CAL ARRAY ‘S (HPV) (Biogenomica Spain). The
extracted DNA eluted in 100 μl Elution buffer (Biogen-
omica Spain) and stored in -20°C. The sensitivity and
specificity of theC L I N I C A LA R R A Y ’ SH P Vk i ti s
92.3% and 89%, respectively [11].
PCR Amplification
Five microliters (5 μl) of eluted DNA were used in the
PCR amplification of pre alliquoted ready to use vials-
kept at -20°C in alliquots (Biogenomica Spain). The PCR
reaction includes two internal controls in order to avoid
the false negative results from the extraction procedure
and from the PCR inhibitors. The first amplifies a 892
bp fragment of the human CFTR gene and indicates the
DNA existence and the second is a 1202 bp fragment
from a modified plasmid and indicates if there is inhibi-
tors or not.
Hybridization
The PCR product denaturated in 95°C for 15 minutes in
iQ Thermocycler and then thawed in 4°C. Five microli-
ters (5 μl) of the PCR product proceeded in hybridiza-
tion on the specific Array Tubes according the
instruction manual (Biogenomica Spain) on the ATS
Workstation (CLONDIAG Chip Technologies GMBH).
The hybridization results were interpreted by the Speci-
fic CLINICAL ARRAYS Human Papilloma virus soft-
ware program which it has been preinstalled and ready
to use on the ATS Workstation (CLONDIAG Chip
Technologies GMBH).
The following 35 HPV types were studied; 6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54,
56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84,
85 and 89. The oncogenic risk of the HPV types detect-
able with CE marked and IVD marked kit of Genomica
are according to the Munoz et al [12].
A recent meta-analysis examined the association
between detection of HPV DNA and high-grade cervical
intraepithelial neoplasia and invasive cervical cancer,
showing a strong association [13].
Statistical Analysis
Statistical analysis was preformed using programs avail-
able in the SPSS statistical package (SPSS 15.0, Chicago,
USA). All variables were tested for normal distribution
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stated otherwise. A two sample t-test was used to assess
differences in continuous variables, while a chi-square
test was used for categorical variables. Univariate binary
logistic analysis was performed to look for the relation-
ship between HPV infection and the variables of interest
in the sample population. Then, multivariate analysis
was performed (backward stepwise method) to look for
independent associations between HPV infection and
the variables of interest. All independent variables in the
multivariate analysis were tested for multicolinearity.
P < 0.05 (two-tailed) was considered statistically
significant.
Results
Characteristics of the study population
The characteristics of the study population are sum-
marized in Additional file 1, Table S1. The study popu-
lation consisted of 225 women aged 16 to 45 years
(mean age ± standard deviation: 30.7 ± 6.8 years). Most
of the participating women had high (68.4%) educa-
tional level, were unmarried (52.4%), had their first sex-
ual intercourse before the age of 20 (67.1%), reported a
single regular sexual partner during the last year
(76.4%). Of the married women 19.5% had at least two
full term pregnancies. 55.1% of the participants
reported more than 3 sexual partners during their life-
time, and 29.3% had more than 5 sexual intercourses
monthly. 45.3% of the study participants had high
monthly income.
Condom was the most common contraceptive method
ever used (58.6%). It is noteworthy that almost the one
third of the study participants did not use any contra-
ceptive method (34.2%). Of the study population, 10.6%
had a history of a previous HPV infection and 48% a
history of sexually transmitted disease. 8.0% had never
done a Pap test, while 66.2% had a Pap test during the
last year without any abnormalities. Only one third of
the women were smokers (39.1%), and 48.8% reported
regular alcohol consumption.
Characteristics of women positive for HPV infection
The age of HPV-positive women (n = 51) was (mean
age ± standard deviation) 28.5 ± 6.7 years. Condom was
the most common contraceptive method ever used
(60.8%), while 29.4% did not use any contraceptive
method. Of the HPV-positive women, 23.5% had a his-
tory of a previous HPV infection and 54.9% a history of
sexually transmitted disease. 13.7% had never done a
Pap test, while 58.8% had a Pap test during the last year.
55.0% of the HPV-positive women were smokers and
62.8% reported regular alcohol consumption (Additional
file 1, Table S1).
HPV prevalence and subtypes
HPV was detected in 51 of the 225 women examined
(22.7%) (6 positive for HPV-6, 12 for HPV-16, 2 for
HPV-18, 1 for HPV-31, 2 for HPV-33, 2 for HPV-39, 3
for HPV-51, 8 for HPV-53, 2 for HPV-58, 2 for HPV-
61, 1 for HPV-62, 3 for HPV-66, 3 for HPV-81, 2 for
HPV-83 and 2 for HPV-84). The percentage of the
newly diagnosed women with HPV infection was 17.3%
(39/225). In addition, it must be mentioned that 12
women with a previous history for HPV infection were
found in the HPV negative subsample. These cases were
included in the HPV-negative group for the further
analysis.
16.4% (37/225) of the study population was infected
with a single type and 6.2% (14/225) was infected with
at least two HPV types. In the entire study population,
HPV-16 was the most common type detected (5.3%)
either as a single type or in combination with other
types, followed by HPV-53 (4.9%). It is noteworthy that
the prevalence of oncogenic HPV-18 was low (0.9%).
Oncogenic (HPV 16, 18, 31, 33, 39, 51, 53, 58) and non-
oncogenic (HPV 6, 61, 62, 66, 81, 83, 84) types were
detected in 14.2% and 8.2% of the HPV-positive women,
respectively.
The prevalence of HPV infection among females aged
21 to 30 years was 26.6% whereas the corresponding
prevalence among females aged 16 to 20 years was
57.1%. In detail, the prevalence of HPV-16 and HPV-53
among females aged 21 to 30 years old were 5.5%, 2.8%,
respectively, whereas the corresponding prevalences
among females aged 16 to 20 years were 14.3% and
14.3%, respectively (Figure 1).
Risk factors for HPV infection
The univariate logistic analysis showed significant asso-
ciations between HPV infection and age [odds ratio
(OR): 0.94, 95% Confidence Intervals (95% CI): 0.89-
0.98], monthly income (OR: 0.65, 95% CI: 0.48-0.89),
marital status (OR: 0.37, 95% CI: 0.18-0.73), number of
full term pregnancies (OR: 0.58, 95% CI: 0.36-0.94),
number of sexual partners (OR: 2.17, 95% CI: 1.50-3.15),
smoking status (OR: 1.42, 95% CI: 1.08-1.85), and alco-
hol consumption (OR: 2.27, 95% CI: 1.18-4.35). No any
significant relationships were found between HPV infec-
tion and educational level, nationality, methods of con-
traception, age at first sexual intercourse, and history of
previous HPV infection or other sexual transmitted dis-
eases (Additional file 2, Table S2).
Multivariate analysis demonstrated, after controlling
for smoking, marital status, and number of full term
pregnancies, that HPV infection was related positively
with alcohol consumption (OR: 2.19, 95% CI: 1.04-4.63)
and number of sexual partners (OR: 2.16, 95% CI:
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0.87-0.99) and monthly income (OR: 0.63, 95% CI: 0.44-
0.89) (Additional file 2, Table S2).
Discussion
Prevalence of HPV DNA in a sample of Greek females
aged 16 to 45 years was 22.7%, with the highest preva-
lence (57.1%) among women aged 16 to 20 years.
The percentage of the newly diagnosed women with
HPV infection was 17.3%. Oncogenic HPV types were
detected in 14.2% of the HPV-positive women. The
overall prevalence of high risk HPV-16, HPV-53 and
HPV-18 were 5.3%, 4.9% and 0.9% respectively. Similar
prevalence of HPV-positive women has been reported in
a large sample of US females aged 14 to 59 years
(26.8%) [14]. Other studies in Europe have yielded simi-
lar findings in healthy women [15] as well as women
with history of cervical cancer [16]. A recent study in
our country demonstrated that HPV DNA was positive
in 23.6% of cytologically normal women [17]. Similar
rates have been confirmed by a previous study in malig-
nant biopsies in Greece [18] and even higher rates in
another study in asymptomatic women [19]. However, a
study in healthy women by Agorastos et al. reported
one of the lowest HPV prevalence ever observed inter-
nationally (2.5%) [20]. Also, low prevalence of HPV-
positive women has been reported in studies from Spain
[21] and Vietnam [22].
HPV-16 was the most prevalent oncogenic type either
as a single type or in combination with other types,
while the prevalence of HPV-18 was low. A lot of stu-
dies in different populations have shown that HPV-16
was the most common among the others HPV types
[22-25]. Even higher prevalence of HPV-16 has been
described in different geographic regions ranging from
43.9% in Asia to 72.4% in Africa in women with invasive
cervical cancer [12]. Furthermore, it is known that HPV-
16 represents the most commonly identified HPV type
in low- and high-grade cervical lesions as well as cervi-
cal cancer worldwide [26]. However, a low prevalence of
HPV-16, HPV-53 and HPV-18 has been reported in the
USA [14]. The prevalence of HPV-18 (0.8%) was similar
to that of the present study [14]. On the contrary, stu-
dies from our country using histological samples have
reported higher prevalence of HPV-18 [18,27,28]. A
study by Kroupis et al., in a sample of Greek women
with a history of cervical lesions reported a higher pre-
valence of HPV-53 [17].
Of the total study population, 16.4% was infected with
a single type and 6.2% was infected with at least two
HPV types. The observed prevalence of multiple infec-
tions is low in comparison with the results from studies
from different countries [29-35]. The presence of multi-
ple infections was 0% in Brazil [29], 5.3% in Morocco
[30], 9.8% in Thailand [31], 14.3% in Philippines [32],
16.7% in Paraguay [33], 28% in The Netherlands [34],
and 39% in Costa Rica [35]. In our country a recent
study showed that the prevalence of multiple infections
was 21.2% [17]. These differences in prevalence of mul-
tiple infections could be due to differences in the techni-
que used or real differences in the prevalence of the
HPV types in the populations studied.
The results of the multivariate analysis demonstrated
that HPV infection was related positively with alcohol
consumption and number of sexual partners, and nega-
tively with age and monthly income. A lot of previous
studies have showed that the main risk factor for HPV
infection was the number of sexual partners [36-38].
Also, alcohol consumption was an important risk factor.
A simply explanation is that alcohol consumption might
lead to unsafe sexual behavior and to less adherences to
contraceptive methods. However, the literature data
regarding the potential relationship between alcohol
consumption and HPV infection are conflicting. A pre-
vious study showed that there is a positive relationship
between alcohol and HPV infection [39], while a recent
one showed no relationship [40]. On the contrary, HPV
infection declined with increasing age. Importantly,
other studies also reported the increaased HPV infection
with aging, suggesting the biological effect, such as HPV
immunity acquired over time [35,38,41]. The same pat-
tern was observed in a previous study from our country
[20]. Finally, low monthly income was a significant
determinant of HPV infection. Two studies in the USA
have showed that high-risk HPV infection is common in
poor women [42,43].
Our study has some limitations. As it is mentioned
above, 12 women with a previous HPV infection were
found in the HPV-negative subgroup. This is partially
Figure 1 The prevalence of HPV-16, HPV-18 and HPV-53
according to the age groups (the values are shown as %).
“black square”, HPV-16; “white square”, HPV-18; “grey square”, HPV-53.
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single negative HPV test result could lead to missed
HPV infection [44] and that HPV test has low specificity
[45]. In addition, the number of the participants as well
as the age range in our study sample was relatively lim-
ited; only women aged 16-45 years were included.
Therefore, the results of the present study can not be
extrapolated to the total female population of our coun-
try. However, since the outpatient clinic is a referral one
the results of the present study give us important infor-
mation regarding the prevalence of HPV infection
among young and middle aged women.
Conclusions
In conclusion, the prevalence of HPV in women attend-
ing an outpatient clinic is high showing the importance
of the early screening as well as the necessity of preven-
tive measures. The number of sexual partners and alco-
hol consumption were the most significant risk factors
for HPV infection, followed by young age and lower
income. Since, the vaccine against the most prevalent
and high risk HPV subtypes is in use in policies regard-
ing prevention of HPV infection might help to reduce
the risk of infection and cervical cancer. However, larger
epidemiological studies in different regions of our coun-
try are needed in order to report the accurate preva-
lence of HPV infection.
Additional file 1: Table S1. The demographic characteristics of the
study population [the variables are expressed as n (%)].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
27-S1.DOC]
Additional file 2: Table S2. Univariate and multivariate logistic analysis:
the association between various parameters with HPV infection in the
study population.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
27-S2.DOC]
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